Clinical Biomarkers Market Size is valued at USD 25.02 Bn in 2023 and is predicted to reach USD 47.25 Bn by the year 2031 at a 8.54% CAGR during the forecast period for 2024-2031.
Clinical biomarkers are molecular biomarkers that offer novel avenues for studying diseases and identifying potential new therapeutic targets. Clinical biomarkers are finding more and more applications in drug development, disease risk assessment, and other areas, and healthcare companies are investing heavily to keep up with industry demand, fueling market growth. Many different assays and methods are utilized in drug discovery to help develop biomarkers for various diseases. Furthermore, infectious diseases can aid in disease prognostic evaluations, treatment decision-making, and pharmaceutical efficacy tracking.
However, the market growth is hampered by the high-cost criteria for the safety and health of the clinical biomarkers market and the product's inability to prevent fog in environments with dramatic temperature fluctuations or high clinical biomarkers market because the lack of investment and infrastructure is the main thing stopping market companies from investing, one of the main reasons for the high capital demand is the expensive instruments. Thus, the desired level of capital investment differs according to the capabilities and size of the newly constructed laboratory. Despite the enormous untapped potential in the global clinical biomarkers market, the prohibitive entry cost limits the industry's ability to reach new audiences and accelerate its progress.
Competitive Landscape
Some Major Key Players In The Clinical Biomarkers Market:
- Abbott Laboratories
- Agilent Technologies, Inc.
- ALCEN
- Arsenal Capital Partners
- Azenta Life Sciences
- Becton, Dickinson and Company
- Bio-Rad Laboratories, Inc.
- bioMérieux S.A.
- BGI
- Broad Institute
- Charles River Laboratories
- Caris Life Sciences
- CENTOGENE N.V.
- Discovery Life Sciences (DLS)
- Enzo Biochem Inc.
- Eurofins Scientific
- Hoffmann-La Roche Ltd
- Illumina, Inc.
- Myriad Genetics, Inc.
- NeoGenomics Laboratories
- Novogene Co., Ltd.
- Personalis Inc.
- QIAGEN N.V.
- Quest Diagnostics Incorporated
- Q2 Solutions
- Thermo Fisher Scientific Inc.
Market Segmentation:
The clinical biomarkers market is segmented based on offering, clinical area, technology, and end user. According to offerings, the market is segmented into products and services. Product segment comprises Efficacy Biomarker (Diagnostic Biomarker, Predictive Biomarker, Prognostic Biomarker), Safety Biomarker, and Validation Biomarker. The Service segment includes Genomic Biomarker Service, Tissue Biomarker Service, Cell Service, Proteomics Service. By clinical area, the market is segmented into cancer biomarkers, cardiac biomarkers, neurological biomarkers, infectious disease, immunological biomarkers, non-invasive prenatal testing, and other clinical areas. By technology, the market is segmented into next-generation sequencing (NGS), polymerase chain reaction (PCR), immunohistochemistry (IHC), enzyme-linked immunosorbent assay (ELISA), and other technologies. By end user, the market is segmented into contract research organizations (CROs), research and academic laboratories, biopharmaceutical and biotech companies, diagnostic centers, and other end users.
Based On The Offering, The Service Segment Is Accounted As A Major Contributor To The Clinical Biomarkers Market
The service clinical biomarkers market is expected to lead with a major global market share. biomarker services help with trial design, execution, and analysis. Diseases can be diagnosed using biomarker testing, which clinical laboratories and diagnostic service providers offer. These services aid in the monitoring and early identification of diseases by facilitating the accurate and dependable detection of biomarkers.
Next-Generation Sequencing (NGS) Segment To Witness Growth At A Rapid Rate
The Next-generation sequencing (NGS) industry makes up the bulk of acrylic acid ester usage because of the advancements in sequencing technology. Nucleotide sequencing (NGS) is a novel and complementary method that enables oncologists to study many cancer genes simultaneously. A patient's tumor tissue that has been surgically removed or biopsied can be utilized for next-generation sequencing, especially in countries like the US, Germany, the UK, China, and India.
In The Region, The North American Clinical Biomarkers Market Holds A Significant Revenue Share
The North American clinical biomarkers market is expected to record the maximum market revenue share in the near future. It can be attributed to the increasing disease burden, new technologies, more informed consumers, encouraging government programs, and better healthcare facilities. In addition, Asia Pacific is projected to grow rapidly in the global clinical biomarkers market due to the increasing need for top-notch healthcare, the growth of regional research initiatives, and the worldwide burden of cancer.
Recent Developments:
- In Feb 2024, Abbott and Fujirebio teamed up to provide a research-use-only test for neurofilament-light chain (NfL). The neurology biomarker assay will be accessible on Abbott's Alinity I instrument and will be provided to researchers doing studies showcasing the usefulness of the NfL biomarker, as stated by the firms. The companies plan to release the test by 2025, making it the initial RUO assay for the Alinity I system. The businesses mentioned that NfL is being investigated as a biomarker for many neurological illnesses such as multiple sclerosis, Alzheimer's disease, and traumatic brain injury.
- In June 2023, Roche declared that its Elecsys® beta-Amyloid (1-42) CSF II (Abeta42) and Elecsys® Total-Tau CSF tests (tTau) had obtained clearance from the U.S. Food & Drug Administration (FDA) under the 510(k) process. The Elecsys AD CSF Abeta42 and tTau assays quantify beta-amyloid and tau proteins, two indicators of Alzheimer's pathology, in persons aged 55 and above undergoing evaluation for the illness.
Clinical Biomarkers Market Report Scope
|
Report Attribute |
Specifications |
|
Market Size Value In 2023 |
USD 25.02 Bn |
|
Revenue Forecast In 2031 |
USD 47.25 Bn |
|
Growth Rate CAGR |
CAGR of 8.54% from 2024 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Bn and CAGR from 2024 to 2031 |
|
Historic Year |
2019 to 2023 |
|
Forecast Year |
2024-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Offering, Clinical Area, Technology, End User |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; Southeast Asia; South Korea |
|
Competitive Landscape |
F. Hoffmann-La Roche AG, Epigenomics AG, Abbott, Thermo Fisher Scientific Inc, General Electric, Eurofins Scientific, Johnson & Johnson Services, Inc., QIAGEN, Bio-Rad Laboratories, Inc., Siemens Healthineers AG, Merck KGaA, PerkinElmer Inc., Agilent Technologies, Inc., DiaMetra, Others |
|
Customization Scope |
Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
